In vivo evaluation of bonding ability and biocompatibility of a novel biodegradable glue consisting of tartaric acid derivative and human serum albumin
✍ Scribed by Masashi Iwasashi; Masataka Sakane; Hirofumi Saito; Tetsushi Taguchi; Tetsuya Tateishi; Naoyuki Ochiai
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 264 KB
- Volume
- 90A
- Category
- Article
- ISSN
- 1549-3296
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
We recently developed a novel biological glue from tartaric acid derivative (TAD) with two active ester groups and human serum albumin (HSA), named TAD‐A. In this study, in vivo experiments were performed to investigate clinical applicability of TAD‐A. TAD was prepared by reacting carboxyl groups of tartaric acid with N‐hydroxysuccinimide in the presence of carbodiimide. Bonding strength was evaluated by using mouse skin closed with TAD‐A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution. Commercially available glues such as fibrin and aldehyde‐based glue were used for comparison. We found that TAD‐A's bonding strength increased significantly with TAD‐A concentration. The bonding strength of 0.5 mmol of TAD‐A in 0.8 mg of 44 w/w % HSA solution was significantly higher than that of fibrin or aldehyde‐based glue (p < 0.01), and that of 0.3 mmol of TAD‐A was significantly higher than of fibrin glue (p < 0.05). To determine toxicity, we implanted disks made from TAD‐A of different TAD concentrations from 0.1 to 0.5 mmol in 0.8 mg of 44 w/w % HSA solution subcutaneously in mice. The inflammatory reaction in surrounding tissue increased with increasing TAD concentration, and then the disks were absorbed. In conclusion, TAD‐A has sufficient bonding strength and comparatively low toxicity in clinical use of 0.3 mmol or less of TAD and 0.8 mL of 44 w/w % HSA solution. © 2008 Wiley Periodicals, Inc. J Biomed Mater Res, 2009